Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.5, Iss.8, 2004-08, pp. : 1781-1798

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anagrelide: A Review of its Use in the Management of Essential Thrombocythaemia

By Wagstaff Antona J. Keating Gillian M.

Drugs, Vol. 66, Iss. 1, 2006-01 ,pp. : 111-131

Adis International

Access to resources Recommend Favorite

Anagrelide is an effective platelet-lowering agent, but its role in the treatment of essential thrombocythaemia has yet to be fully determined

By Adis International Limited

Drugs & Therapy Perspectives, Vol. 22, Iss. 11, 2006-11 ,pp. : 1-5

Adis International

Access to resources Recommend Favorite

Sapropterin: A Review of its Use in the Treatment of Primary Hyperphenylalaninaemia

By Sanford Mark Keating Gillian M.

Drugs, Vol. 69, Iss. 4, 2009-01 ,pp. : 461-476

Adis International

Access to resources Recommend Favorite

Anagrelide/hydroxycarbamide: Essential thrombocythaemia transformation to AML or MDS: 17 case reports

Reactions Weekly, Vol. 1, Iss. 1334, 2011-01 ,pp. : 8-9

Adis International

Access to resources Recommend Favorite

Eltrombopag: A Review of its Use in Treatment-Refractory Chronic Primary Immune Thrombocytopenia

By Garnock-Jones Karly P.

Drugs, Vol. 71, Iss. 10, 2011-07 ,pp. : 1333-1353

Adis International

Access to resources Recommend Favorite